Open in interactive viewer → charts, metric popovers & call review

Beyond Air Finally Sounds Like a Sales Company — Right as Its Approval Clock Slips Again

A record $2.3M quarter, a fourfold pipeline and a doubling win rate, set against an FDA audit that has been 'a couple of months away' since June and an $8M guide that quietly implies a Q4 step-down.
XAIR · Earnings Call · 2026-11-11

The vocabulary changed before the numbers did

Beyond Air's September quarter produced the first genuinely commercial-looking print in its history: revenue of $2.3 million, a genuine record, with gross profit flipping positive at roughly $200,000 and an 8% gross margin against negative 16% a year earlier. The net loss of $7.8 million, or $3.76 a share on an obviously reverse-split-adjusted base, is not the interesting part. The interesting part is what management spent its forty minutes talking about. For at least two years, this company's keyword fingerprint was regulatory: PMA supplement, FDA approval, audit, inspection, paperwork. In the current quarter's ranked themes, the top of the list reads like a territory sales review — win rate, average deal size, commercial pipeline, direct sales, and expanding market penetration. "PMA supplement," which sat at the very top of the company's keyword set just two quarters ago, has fallen out of the top 30 entirely. That evaporation of the regulatory vocabulary is the real tell: the centre of gravity at Beyond Air moved from a filing to a funnel, at least in how the company wants to be heard. The funnel evidence is specific. On the pipeline: “our pipeline from Q1 of this year, it's grown close to fourfold” — Robert Goodman, Chief Executive Officer · 2026-11-11. On deal size: “Our average deal size is about the same, and I could say roughly it's right around $250,000” — Robert Goodman, Chief Executive Officer · 2026-11-11, with a range from $30,000 to more than $1 million. And on why the win rate is climbing, Bob Goodman offered a claim worth flagging: “there's less competitors in the field right now, so we're expecting just based off of that to have a higher win rate” — Robert Goodman, Chief Executive Officer · 2026-11-11. A competitor exiting is the most durable kind of tailwind a small device maker can get — and also the least verifiable from the outside.

The audit that keeps being 'a couple of months' away

The regulatory side is where the transcript earns its tension. Frank Takkinen of Lake Street asked the question every long-suffering holder wanted asked:

it seemed like it was kind of a near-term event that was going to be complete in a few months, and it feels like that maybe took a little bit longer than anticipated.

Frank Takkinen, Analyst · 2026-11-11
Goodman's reply was a flat denial, and then a description of what remains: audit readiness complete mid-December, an audit of "a day and a half," a few weeks for feedback, then a signature. “It's now just the audit part... once that happens, we expect to hear back from them within a few weeks.” — Robert Goodman, Chief Executive Officer · 2026-11-11 That plausibly puts the second-generation approval into the first quarter of calendar 2027. Read the sequence across calls, though. In February, the gating item was the contract manufacturer: “We still are waiting on the work to be completed with our contract manufacturer, so we can be inspected” — Steven Lisi, Chief Executive Officer · 2026-02-13. In June: “We're looking forward to doing our audits in the upcoming couple of months” — Robert Goodman, Chief Executive Officer · 2026-06-26. In August: “likely that would be a Q4 period. We're still in H2” — Robert Goodman, Chief Executive Officer · 2026-08-13. Now it is mid-December readiness with approval drifting into Q1. Each individual explanation is reasonable — repeatability testing, altitude testing, paperwork rounds — but the pattern is a milestone that recedes by roughly one quarter per quarter. What makes this less alarming than it reads is the shape of the guidance. The $16–18 million calendar 2027 target bakes in second generation system revenue only for Q2, Q3 and Q4 — deliberately no Gen 2 in the first quarter. So a Q1 approval slip costs nothing to the printed number. What it does cost is credibility compounding, because the 2027 guide already asks for roughly two to two-and-a-quarter times the 2026 guide, and the 2026 guide itself carries an awkward arithmetic detail: with $1.9 million in Q1, $1.76 million in Q2 and $2.3 million in Q3, reaffirming $8 million for the calendar year implies a fourth quarter of about $2.0 million — a sequential decline from the record just posted. The reaffirmation is safer than it sounds, and less impressive than it sounds, simultaneously.

Shrinking to a single asset

The quarter's quietest strategic move is a narrowing. NeuroNOS is being sold to UNIVO Pharmaceuticals, Beyond Cancer is being shopped for partnerships, and LungFit GO — which just won breakthrough device designation in NTM-PD — was explicitly starved: “we do not currently plan to allocate resources to further development of LungFit GO in 2027” — Robert Goodman, Chief Executive Officer · 2026-11-11. One asset, one approval, one launch. That is the correct call for a company with this balance sheet, and it shows up in the keyword set as newly minted concerns like restricted cash and a one-off charge for scrap material that helped push other expense to $2.2 million from $600,000. The balance sheet is the binding constraint. Reported cash, equivalents, restricted cash and marketable securities total $18.5 million — but that includes $4.8 million restricted, $2.7 million sitting in held-for-sale NeuroNOS, and $700,000 at Beyond Cancer. Strip the encumbrances and the effective net cash position is negative $4 million, against a 2021 peak of $93 million. Operating discipline is real: R&D fell to roughly $2 million from a $6 million peak as the second-generation development wound down, and SG&A stepped down too. Free cash flow of about negative $6 million a quarter is a slower bleed, not a stopped one.

Nobody else is having this conversation

Scan the market: across the last twelve quarters of top-75 global themes, and across every company that reported in the past five days, inhaled nitric oxide, cylinder-free delivery and pulmonary hypertension in the neonatal ICU appear essentially nowhere. There is no sector wave here to ride or to hide behind. Beyond Air's themes are company-unique, which cuts both ways — the pipeline is its own, and so is the risk. The tape agrees with the sceptics. The stock is down more than 70% in ninety trading days from a July peak near $8.82, and has shed essentially all of its value since 2017 — a drawdown of 99.9%. At roughly 1.1x price to revenue, the equity is priced as an option on a single FDA signature, not on the sales organisation Goodman spent the call describing. The last three weeks of trading show a modest bounce, but a bounce off a 70% decline is not a verdict. The bottom line: this was the best commercial quarter Beyond Air has printed and the most confident its commercial commentary has ever sounded — new sales vocabulary, a fourfold pipeline, a competitor gap, a $250,000 average deal moving higher with Gen 2. But the approval clock slipped another quarter, the free cash position turned negative on an effective basis, and the $8 million guide for this year mathematically requires a softer fourth quarter than the third. The story has migrated from "will the FDA approve it" to "can they actually sell it" — which is progress, and still unresolved.